{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:01:27Z","timestamp":1787763687520,"version":"build-2784847793"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.hbpd.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T22:40:27Z","timestamp":1678920027000},"page":"14-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Stereotactic body radiotherapy in pancreatic adenocarcinoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Carolina","family":"de la Pinta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2023.03.002_bib0001","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hbpd.2023.03.002_bib0002","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0003","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Pancreatic Adenocarcinoma NCCN Evidence BlocksTM. Version 2.2022. Available from https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1455."},{"key":"10.1016\/j.hbpd.2023.03.002_bib0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2015.11.004","article-title":"Adjuvant therapy for pancreas cancer in an era of value based cancer care","volume":"42","author":"Ahn","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0005","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0006","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0007","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semradonc.2017.02.005","article-title":"Integration of stereotactic body radiation therapy into the multidisciplinary management of pancreatic cancer","volume":"27","author":"Rosati","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0008","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0009","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2014.06.066","article-title":"Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity","volume":"90","author":"Pollom","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0010","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","article-title":"Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer","volume":"72","author":"Schellenberg","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.radonc.2014.10.015","article-title":"SBRT in pancreatic cancer: what is the therapeutic window?","volume":"114","author":"Brunner","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0012","first-page":"246","article-title":"Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas","volume":"52","author":"Zimmermann","year":"2005","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0013","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1533034616650778","article-title":"Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study","volume":"16","author":"Comito","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.17140\/POJ-3-110","article-title":"The evolving field of stereotactic body radiation therapy in pancreatic cancer","volume":"3","author":"Ghaly","year":"2019","journal-title":"Pancreas (Fairfax)"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0015","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.hpb.2020.11.004","article-title":"Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer","volume":"23","author":"Zakem","year":"2021","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0016","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jso.24375","article-title":"Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: is radiation necessary in the modern era of chemotherapy?","volume":"114","author":"Kim","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0017","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/SLA.0000000000001547","article-title":"Preoperative gemcitabine-based chemoradiation therapy for borderline resectable pancreatic cancer: impact of venous and arterial involvement status on surgical outcome and pattern of recurrence","volume":"264","author":"Takahashi","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0018","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ijrobp.2017.12.287","article-title":"Management of borderline resectable pancreatic cancer","volume":"100","author":"Toesca","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0021","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1245\/s10434-014-4274-5","article-title":"The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience","volume":"22","author":"Moningi","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0022","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2013.02.022","article-title":"Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated","volume":"86","author":"Chuong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0023","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2020.01.007","article-title":"Neoadjuvant treatment strategies for resectable pancreas cancer: a propensity-matched analysis of the National Cancer Database","volume":"143","author":"Xiang","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0024","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/0284186X.2016.1256497","article-title":"Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy","volume":"56","author":"Mellon","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0025","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1245\/s10434-010-0943-1","article-title":"Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation","volume":"17","author":"Katz","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0026","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijrobp.2014.02.031","article-title":"Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy","volume":"89","author":"Dholakia","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 3","key":"10.1016\/j.hbpd.2023.03.002_bib0027","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2021.39.3_suppl.377","article-title":"Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas","volume":"39","author":"Katz","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0028","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1186\/s12885-021-08666-y","article-title":"AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer","volume":"21","author":"Oar","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0029","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.surg.2017.11.027","article-title":"Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: the impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy","volume":"163","author":"Blair","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0030","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/MPA.0000000000001584","article-title":"Radiation as a single-modality treatment in localized pancreatic cancer","volume":"49","author":"Shaib","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0031","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12029-016-9909-2","article-title":"Five-fraction stereotactic body radiation therapy (SBRT) and chemotherapy for the local management of metastatic pancreatic cancer","volume":"49","author":"Lischalk","year":"2018","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0032","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.ijrobp.2017.08.006","article-title":"A novel absorbable radiopaque hydrogel spacer to separate the head of the pancreas and duodenum in radiation therapy for pancreatic cancer","volume":"99","author":"Rao","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0033","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijrobp.2005.07.002","article-title":"Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer","volume":"63","author":"Koong","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0034","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijrobp.2009.08.046","article-title":"Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer","volume":"78","author":"Mahadevan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0036","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1245\/s10434-010-1019-y","article-title":"Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration","volume":"17","author":"Polistina","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0037","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijrobp.2010.05.006","article-title":"Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer","volume":"81","author":"Schellenberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0038","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jss.2011.07.044","article-title":"Stereotactic body radiation therapy for nonresectable tumors of the pancreas","volume":"174","author":"Goyal","year":"2012","journal-title":"J Surg Res"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0039","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1748-717X-8-44","article-title":"Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety","volume":"8","author":"Gurka","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0040","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/1748-717X-8-254","article-title":"Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer","volume":"8","author":"Rajagopalan","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0041","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1748-717X-8-148","article-title":"SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience","volume":"8","author":"Tozzi","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0042","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MEG.0000000000000283","article-title":"Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer","volume":"27","author":"Lin","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0043","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0044","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2016.05.010","article-title":"A phase 1 study of stereotactic body radiation therapy dose escalation for borderline resectable pancreatic cancer after modified FOLFIRINOX (NCT01446458)","volume":"96","author":"Shaib","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1748-717X-8-27","article-title":"Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection","volume":"8","author":"Habermehl","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0046","first-page":"34","article-title":"Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer","volume":"7","author":"Wilkowski","year":"2006","journal-title":"JOP"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0047","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00066-014-0610-8","article-title":"Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis","volume":"190","author":"Nakamura","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0048","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejso.2016.12.012","article-title":"Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: a retrospective study","volume":"43","author":"Comito","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0049","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.adro.2017.01.003","article-title":"Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma","volume":"2","author":"Koong","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0050","first-page":"343","article-title":"Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions","volume":"4","author":"Wild","year":"2013","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0051","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1748-717X-7-74","article-title":"Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas","volume":"7","author":"Lominska","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0052","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1046\/j.1440-1827.2001.01258.x","article-title":"Secondary tumors of the pancreas: clinicopathological study of 103 autopsy cases of Japanese patients","volume":"51","author":"Nakamura","year":"2001","journal-title":"Pathol Int"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0053","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0054","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ijrobp.2013.09.005","article-title":"Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design","volume":"87","author":"Dholakia","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0055","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers2031513","article-title":"Neural invasion in pancreatic cancer: the past, present and future","volume":"2","author":"Demir","year":"2010","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hbpd.2023.03.002_bib0056","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.suronc.2017.01.007","article-title":"The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - a systematic review and meta-analysis","volume":"26","author":"Schorn","year":"2017","journal-title":"Surg Oncol"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S149938722300036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S149938722300036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:43:39Z","timestamp":1761493419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S149938722300036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S149938722300036X"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2023.03.002","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiotherapy in pancreatic adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}